IP Library Granted Patent US 12,121,528
Granted Patent B2
US 12,121,528 · App. 17/944,006 · Granted Oct 22, 2024

Bacterial DNA gyrase inhibitors and methods of use thereof

Inventors: Fenfei Leng (Palmetto Bay, FL); Eddy Alfonso (Miami, FL); Zifang Deng (Miami, FL)
Assignee: The Florida International University Board of Trustees
A61K31/7048A61K31/185A61K31/192A61K31/196A61K31/24A61K31/352A61K31/366A61K31/381A61K31/404A61K31/4155A61K31/4184A61K31/4196A61K31/427A61K31/429A61K31/433A61K31/443A61K31/473A61K31/475A61K31/496A61K31/498A61K31/513A61K31/519A61K31/52A61K31/5377A61K31/7076A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,121,528
App. No.
17/944,006
Granted
Oct 22, 2024
Kind
B2
Abstract

The subject invention provides fluorophore-quencher nucleic acid molecules comprising relaxed or supercoiled DNA molecules, and their use in rapid and efficient high-throughput screening (HTS) assays to screen and identify compounds that inhibit DNA gyrases. These compounds can be used as antibiotics for treating bacterial infections, especially, multidrug resistant bacterial infections.

Claims (13)

1. A method for inhibiting a DNA gyrase, comprising contacting the DNA gyrase with compound 154; and measuring the DNA gyrase activity.

2. A method for treating a bacterial infection in a subject via the inhibition of DNA gyrase of the bacterium, the method comprising administering, to the subject in need of such treatment, a pharmaceutical composition comprising compound 154; and measuring bacterial growth, the bacterial infection being caused by E. coli, S. aureus , MRSA, or B. subtilis.

3. The method of claim 2 , said pharmaceutical composition being administered through oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, transdermal, vaginal, intramuscular, intraperitoneal, intravenous, intra-arterial, intracerebral, or intraocular administration.

4. The method of claim 2 , the bacterial infection being caused by MRSA.

5. A method for inhibiting the growth of a bacterium, the method comprising contacting the bacterium with compound 154, measuring DNA gyrase activity in the bacterium and measuring the bacterial growth.

6. The method of claim 2 , the bacterial infection being caused by E. coli.

7. The method of claim 2 , the bacterial infection being caused by S. aureus.

8. The method of claim 2 , the bacterial infection being caused by B. subtilis.

9. The method of claim 5 , the bacterium being MRSA.

10. The method of claim 5 , the bacterium being M. tuberculosis.

11. The method of claim 5 , the bacterium being E. coli.

12. The method of claim 5 , the bacterium being S. aureus.

13. The method of claim 5 , the bacterium being B. subtilis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 24, 2024
From: FLORIDA INTERNATIONAL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066368/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: LENG, FENFEI; ALFONSO, EDDY; DENG, ZIFANG
To: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Reel/Frame 061509/0722 →
Continuity (2)
Provisional Application 63243378 · Sep 13, 2021
Related Publication 20230136466A1 · May 4, 2023